The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine has revealed plans to present scientific posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress.
The company also announced its participation in an upcoming investor conference. No further details have been provided in the announcement.
View post on X Loading...
Earlier this year, Editas Medicine secured approval to launch its first in human clinical trial of EDIT-401 for hyperlipidemia patients, according to company filings. The move marked a key step as the firm advances its gene editing therapies. The company continues to announce new research and investor engagements.